Conferences - Results from #7960

EAU 2017: State of the Art Debate - Evidence for extent of lymphadenectomy in urothelial bladder cancer March 26, 2017

EAU 2017: Debate - Do we need to follow-up in low grade bladder tumor after 12 months?-Yes (EAU Guidelines) March 26, 2017

EAU 2017: Perfect adjuvant treatment March 26, 2017

EAU 2017: Perfect transurethral resection March 26, 2017

EAU 2017: Is further screening of Asian men with low baseline prostate-specific antigen levels (≤ 1ng/ml) worthwhile March 26, 2017

EAU 2017: Comparing 20,000 open prostatectomy (RRP) cases to 5,000 robotic prostatectomy (RALP) cases, he noted no differences in oncologic outcome or urinary continence March 26, 2017

EAU 2017: Quality of life after robotic, lap, and open surgery: real different? March 26, 2017

EAU 2017: Debate on Kidney Cancer – partial nephrectomy is better done with the robot - Con March 26, 2017

EAU 2017: Pure histological variants are associated with poor survival at radical cystectomy in patients with bladder cancer March 26, 2017

EAU 2017: Efficacy of long acting sandostatin on reducing mucus production in patients with ileal neobladder March 26, 2017

EAU 2017: Increasing use of incontinent urinary diversion: A total population analysis of radical cystectomies in Germany from 2006 to 2013 March 26, 2017

EAU 2017: The use of antibiotic prophylaxis in patients undergoing radical cystectomy for bladder cancer March 26, 2017

EAU 2017: 20-gene expression signature to predict lymph node positive disease at radical cystectomy for muscle-invasive bladder cancer: Not validated March 26, 2017

EAU 2017: Can pre-operative functional status (FS) or gait velocity (GV) replace cardiopulmonary exercise testing (CPET) as an independent predictor of survival and complications following radical cystectomy (RC)? March 26, 2017

EAU 2017: The diverse genomic landscape of low-risk prostate cancer March 26, 2017

EAU 2017: Prostate cancer screening in high risk families: Should PSA testing be performed yearly in first degree relatives with baseline PSA ≤1ng/ml? March 26, 2017

EAU 2017: Malignancies in male BRCA mutation carriers – results from a prospectively screened cohort of patients enrolled to a dedicated male BRCA clinic March 25, 2017

EAU 2017: At what age should a PSA-based screening program start? 20-year results from the Göteborg randomized population-based prostate cancer screening study March 25, 2017

EAU 2017: An evaluation of a selective prostate cancer screening program using family history as a supplementary screening tool to PSA: Results from the ProtecT trial March 25, 2017

EAU 2017: APACHE: An open label, randomized, phase 2 study of the anti-Programmed Death-Ligand 1 (PD-L1) Durvalumab (D, MEDI4736), alone or in combination with Tremelimumab (T), in patients (pts) with advanced germ cell tumors (GCT) March 25, 2017

Page 399 of 507